THE ROLE OF MICROBIOTA IN THE DEVELOPMENT OF AUTOIMMUNE DISEASES

Abstract

Autoimmune diseases are increasingly recognized as global health challenges, characterized by the immune system’s aberrant attack on the body’s own tissues. Recent studies highlight the gut microbiota as a central regulator of immune function, with imbalances in microbial composition—referred to as symbiosis—implicated in the pathogenesis of conditions such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes.This study systematically investigates the immunological mechanisms influenced by microbial metabolites, such as short-chain fatty acids (SCFAs), bile acids, and indole derivatives, which modulate regulatory T cell (Treg) function and cytokine signaling. Quantitative analyses were performed on microbial species abundance, immune marker levels, and metabolite profiles, supported by complex statistical visualizations.The results revealed a consistent association between decreased levels of SCFA-producing bacteria and elevated inflammatory cytokines, alongside reduced Treg counts in autoimmune-prone individuals. The study also demonstrated that microbial imbalance correlates with compromised gut barrier integrity and increased systemic inflammation. Data simulations further supported the therapeutic potential of probiotics and dietary interventions in restoring microbial equilibrium and attenuating immune hyperactivation.In conclusion, the findings affirm that gut microbiota composition plays a pivotal role in modulating immune homeostasis and influencing autoimmune disease outcomes. Microbiota-targeted strategies, including personalized probiotics and fecal microbiota transplantation, offer promising avenues for future interventions. Continued research in microbiome-based immunomodulation may redefine clinical approaches for autoimmune disease prevention and management.